Table 2.
Patient demographic information and clinical characteristics at initial diagnosis.
| Characteristic | Number | Percentage |
|---|---|---|
| Total patients | 48 (mean age 48.1 years) | 100 |
| Affected side | ||
| right | 26 | 54.2 |
| left | 22 | 45.8 |
| Histologic type | ||
| ductal | 42 | 87.5 |
| lobular | 5 | 10.4 |
| other | 1 | 2.1 |
| Tumor size a (pT) | ||
| T1a-b | 12 | 25 |
| T1c | 15 | 31.3 |
| T2 | 11 | 22.9 |
| T3 | 5 | 10.4 |
| Nodal affectation a (pN) | ||
| N0 | 14 | 29.2 |
| N1 | 22 | 45.8 |
| N2a-b | 4 | 8.3 |
| N3a | 2 | 4.2 |
| N3b | 1 | 2.1 |
| Mestatase a,b (M) | ||
| M0 | 20 | 39.6 |
| M1 | 1 | 2.1 |
| Mx | 22 | 43.8 |
| TNM clinical stage a | ||
| IA | 13 | 27.1 |
| IB | 0 | 0 |
| IIA | 16 | 33.3 |
| IIB | 4 | 8.3 |
| IIIA | 6 | 12.5 |
| IIIB | 0 | 0 |
| IIIC | 3 | 6.3 |
| IV | 1 | 2.1 |
| Estrogen receptor positivity | ||
| negative | 17 | 54.2 |
| low | 4 | 54.2 |
| moderate | 11 | 54.2 |
| strong | 16 | 54.2 |
| Progesterone receptor positivity | ||
| negative | 24 | 50 |
| low | 8 | 16.7 |
| moderate | 7 | 14.62 |
| strong | 9 | 18.8 |
| Her2 positivity | ||
| 0 | 33 | 68.8 |
| 1 | 15 | 31.3 |
| Histologic grade c | ||
| well | 1 | 2.1 |
| moderate | 20 | 41.7 |
| poor | 26 | 54.2 |
a Five patients had no available information; b Twenty-two patients had no available or unknown M stage, and one had a de novo metastatic breast cancer. c One patient had no available information. pT and pN are the pathological T and N stage, respectively. Her2 = human epidermal growth factor receptor 2. Stage classification was according to the seventh edition of the AJCC Cancer Staging Manual [17].